Looking to improve your lab’s efficiency and streamline your nLC-MS processes? Whether you’re new to Evosep or simply curious about how we can simplify your workflows, this session offers valuable insights for labs at all levels.
This publication by the Trudel group describes the development of a non-invasive MS-based assay, called EasyM, which is used to assess minimal residual disease, a measure of depth of remission to treatment, which has become an important parameter in assessing the disease burden in multiple myeloma.
